<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181713</url>
  </required_header>
  <id_info>
    <org_study_id>SBK-OcuFResis</org_study_id>
    <nct_id>NCT01181713</nct_id>
  </id_info>
  <brief_title>Change in Ocular Flora Resistance From Repeated Topical Antibiotic Use</brief_title>
  <official_title>Antibiotic Resistance of Ocular Surface Flora After Continued Use of Topical Antibiotics Post Intravitreal Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if antibiotic resistance of the ocular surface&#xD;
      flora to the 4th generation fluoroquinolones will increase after repeated use of topical&#xD;
      antibiotics for three days post intravitreal injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with intravitreal (IVT) injections has increased during the last several years as&#xD;
      evidence has accumulated demonstrating the efficacy of anti-vascular endothelial growth&#xD;
      factor agents in the treatment of neovascular age-related macular degeneration (AMD) and&#xD;
      various retinal vascular diseases.&#xD;
&#xD;
      Although IVT injections are generally safe, infectious endophthalmitis is a rare but&#xD;
      devastating complication, and the risk of morbidity and vision loss from endophthalmitis is&#xD;
      high. The objective is to examine the change in antibiotic resistance of ocular surface flora&#xD;
      with repeated prophylactic use of antibiotics after IVT injection for AMD.&#xD;
&#xD;
      Yin, V. T., Weisbrod, D. J., Eng, K. T., Schwartz, C., Kohly, R., Mandelcorn, E., Lam, W.,&#xD;
      Daneman, N., Simor, A., &amp; Kertes, P. J. (2013). Antibiotic resistance of ocular surface flora&#xD;
      with repeated use of a topical antibiotic after intravitreal injection. JAMA ophthalmology,&#xD;
      131(4), 456-461.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ocular flora resistance to 4th generation fluoroquinolone</measure>
    <time_frame>1 year</time_frame>
    <description>Outcome will examine the change in amount, type and antibiotic resistance profile of ocular surface flora over the 3 months. Charcoal swab of the conjunctiva will be cultured, organisms grown will be identified and resistance to moxifloxacin will be quantified by minimal inhibitory resistance (MIC).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Increased Drug Resistance</condition>
  <condition>Infection Resistant to Quinolones and Fluoroquinolones</condition>
  <arm_group>
    <arm_group_label>No Antibiotic</arm_group_label>
    <description>No prophylactic antibiotic post intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylactic Antibiotic</arm_group_label>
    <description>Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient recruitment would be from the Sunnybrook Health and Sciences Centre Department of&#xD;
        Ophthalmology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients scheduled for intravitreal injection for neovascular age-related macular&#xD;
             degeneration (ARMD)&#xD;
&#xD;
          -  65 years or older&#xD;
&#xD;
          -  able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnosed with an active ocular, periocular or systemic infection&#xD;
&#xD;
          -  previously received treatment with an intravitreal injection&#xD;
&#xD;
          -  previously treated with antibiotics in the past three months&#xD;
&#xD;
          -  unable to attend the scheduled follow-up appointments or to complete treatment for any&#xD;
             reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Kertes, MD, FRCSC</last_name>
    <role>Study Chair</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivian T Yin, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Weisbrod, MD, FRCSC</last_name>
    <role>Study Director</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health and Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Peter Kertes</investigator_full_name>
    <investigator_title>chief, department of ophthalmology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

